On Tuesday, Zogenix, Inc. (NASDAQ:ZGNX)’s shares inclined 1.18% to $1.72.
Zogenix, Inc. (ZGNX) a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, recently declared new data demonstrating sustained efficacy and tolerability for patients treated with low-dose fenfluramine as an adjunctive therapy for Dravet syndrome. The data was authored by world-renown experts in the field of Dravet syndrome, Berten Ceulemans, M.D., Ph.D. and Lieven Lagae, M.D., Ph.D., from the Universities of Antwerp and Leuven in Belgium, and was presented at the European Paediatric Neurology Society meeting taking place this week in Vienna, Austria (see study data here). Zogenix intends to initiate Phase 3 clinical studies for ZX008, the Company’s investigational proprietary pediatric formulation of low-dose fenfluramine, during the second half of 2015. ZX008 is designated as an orphan drug in both the U.S. and Europe for the treatment of Dravet syndrome.
Patients with Dravet syndrome experience frequent, severe and potentially life-threatening seizures that typically start in the first year of life. These seizures do not respond to standard anti-epileptic medications and current treatment options are very limited.
Nektar Therapeutics (NASDAQ:NKTR)’s shares gained 2.61% to $11.78.
Nektar Therapeutics (NKTR) and The University of Texas MD Anderson Cancer Center today announced a research collaboration that includes a Phase 1/2 clinical study to evaluate NKTR-214, a CD122-biased cytokine designed to preferentially stimulate production of CD8-positive T cells, which are tumor killing cells found naturally in the body. CD122, which is also known as the Interleukin-2 receptor beta sub-unit, is a key signaling receptor that is known to increase proliferation of these effector T cells.1
The agreement covers a Phase 1/2 study to evaluate NKTR-214 in a variety of tumor types as a monotherapy and in combination with other therapies, counting PD-1 pathway inhibitors. Nektar and MD Anderson expect to initiate the first dose-escalation clinical study later this year. The two organizations will also conduct translational research to identify predictive biomarkers that can be used in the future development of NKTR-214.
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
At the end of Tuesday’s trade, Archer Daniels Midland Company (NYSE:ADM)‘s shares dipped -0.51% to $52.76.
Archer Daniels Midland Company (ADM) declared that it has attained tree nut and seed processing assets and operations in Modesto, California, from California Gold Almonds, adding critical processing capacity on top of ADM’s existing West Coast nut operations in Lodi and Stockton. Under the terms of the deal, ADM is acquiring the lease to the brand-new Modesto processing plant, and taking ownership of assets—counting processing equipment—at the facility.
Archer-Daniels-Midland Company procures, transports, stores, processes, and merchandises agricultural commodities and products. The company’s Oilseeds Processing segment originates, merchandises, crushes, and processes soybeans and soft seeds into vegetable oils and protein meals. It offers ingredients for the food, feed, energy, and industrial products industries; crude vegetable and salad oils; refined oils; oilseed protein meals; natural health and nutrition products, and other specialty food and feed ingredients; and cottonseed flour and cotton cellulose pulp.
Herbalife Ltd. (NYSE:HLF), ended its Tuesday’s trading session with 1.70% gain, and closed at $53.11.
Herbalife Ltd. (HLF) declared an expansion of the company’s global corporate affairs team based in Los Angeles. The company welcomes three practiced individuals to the global leadership team: Ric Hobby, who will serve as the company’s senior vice president for global government relations; Megan Jordan, who will serve as the company’s senior vice president for global corporate communications; and Randall Popelka, who will serve as vice president, government and industry affairs.
Two present members of the team, Julian Cacchioli and Elaine Pacheco will take on new responsibilities within the global corporate affairs team as the office undergoes a noteworthyexpansion and reorganization.
Herbalife Ltd., a nutrition company, develops and sells weight administration, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products. The company offers science-based products in four principal categories, counting weight administration; targeted nutrition; energy, sports, and fitness; and outer nutrition.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
